Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

0.0%

0 terminated out of 20 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

15%

3 trials in Phase 3/4

Results Transparency

40%

6 of 15 completed with results

Key Signals

6 with results100% success

Data Visualizations

Phase Distribution

14Total

Not Applicable (2)

P 1 (5)

P 2 (4)

P 3 (1)

P 4 (2)

Trial Status

Completed15

Withdrawn2

Recruiting1

Unknown1

Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (20)

Showing 20 of 20 trials

NCT06481150Phase 4CompletedPrimary

A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.

NCT06578754Not Yet RecruitingPrimary

Validation Testing for Plasma Oxalate Levels in the Biochemical Laboratory at the Galilee Medical Center, in Collaboration With the Biochemistry Laboratory at CHARITE Hospital in Berlin, and Testing the Relationship Between Oxalate Levels and Vitamin C Levels in Plasma

NCT02780297RecruitingPrimary

Prospective Research Rare Kidney Stones (ProRKS)

NCT06138327Phase 1WithdrawnPrimary

A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

NCT05443932Phase 4Unknown

Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients

NCT04119765Completed

Plasma Oxalate in Patient With Short Bowel

NCT03095885Not ApplicableCompleted

A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria

NCT04756024CompletedPrimary

Reference Interval of Spot Urinary Oxalate to Creatinine Ratio in Children